Treatment of degenerations and light-induced damage to the retina

A method for the prevention or treatment of a light-induced damage and/or degeneration of the retina in an individual, comprising administering the individual with an effective amount of a compound of the following formula (I):

• wherein:
• a represents 0 or 1,
• b represents a single bond or a double bond,
• c represents a single bond or a double bond,
• d represents 0 or 1,
• X represents an oxygen or nitrogen atom, provided that when X represents an oxygen atom then d has the value of 0 and when X represents a nitrogen atom then d has the value of 1,
• R1, R2, R3, and R4, which are the same or different, represent a hydrogen atom, a halogen atom, in particular selected from F, Cl, Br, or I, a hydroxyl group, or an alkoxyl group having 1 or 2 carbon atoms,
• R5 and R6, which are the same or different, represent a hydrogen atom, an alkyl or cycloalkyl group having from 1 to 6 carbon atoms, or an aryl group having 6 carbon atoms in which the aromatic ring may be substituted by one or more halogen atoms or one or more hydroxyl groups, alkoxyl groups having 1 or 2 carbon atoms, trifluoromethyl groups or nitro groups,
• R7 represents a hydrogen atom, a hydroxyl group, or an alkyl or hydroxyalkyl group having from 1 to 3 carbon atoms,
• R8 represents an oxygen atom or a —NR9R10 group, R9 and R10, which are the same or different, representing a hydrogen atom, a hydroxyl group, or an alkyl or hydroxyalkyl group having from 1 to 3 carbon atoms, provided than when R8 represents an oxygen atom then a has the value 1, b represents a single bond and c represents a double bond and that when Rg represents a —NR9R10 group then a has the value 0, b represents a double bond and c represents a single bond,
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising as active ingredients

• at least one compound of the following formula (I),
• wherein:
• a represents 0 or 1,
• b represents a single bond or a double bond,
• c represents a single bond or a double bond,
• d represents 0 or 1,
• X represents an oxygen or nitrogen atom, provided that when X represents an oxygen atom then d has the value of 0 and when X represents a nitrogen atom then d has the value of 1,
• R1, R2, R3, and R4, which are the same or different, represent a hydrogen atom, a halogen atom, in particular selected from F, Cl, Br, or I, a hydroxyl group, or an alkoxyl group having 1 or 2 carbon atoms,
• R5 and R6, which are the same or different, represent a hydrogen atom, an alkyl or cycloalkyl group having from 1 to 6 carbon atoms, or an aryl group having 6 carbon atoms in which the aromatic ring may be substituted by one or more halogen atoms or one or more hydroxyl groups, alkoxyl groups having 1 or 2 carbon atoms, trifluoromethyl groups or nitro groups,
• R7 represents a hydrogen atom, a hydroxyl group, or an alkyl or hydroxyalkyl group having from 1 to 3 carbon atoms,
• R8 represents an oxygen atom or a —NR9R10 group, R9 and R10, which are the same or different, representing a hydrogen atom, a hydroxyl group, or an alkyl or hydroxyalkyl group having from 1 to 3 carbon atoms, provided than when Rg represents an oxygen atom then a has the value 1, b represents a single bond and c represents a double bond and that when Rg represents a —NR9R10 group then a has the value 0, b represents a double bond and c represents a single bond,
• or a pharmaceutically acceptable salt thereof, and
• at least one additional compound useful for the prevention or treatment of a light-induced damage and/or a degeneration of the retina,
• optionally in association with a pharmaceutically acceptable vehicle.